Table 2.

Clinical trials

Trial	Dosage range	Duration	Patients	Results	References
Phase I	0.25’30 mg/eye	3 months	15	80% had stabilized or improved vision with 26.7% showing improvement, no toxicity	Guyer et al 2002; Eyetech Study Group 2002
Phase II	multiple intravitreal injections with or without PDT	3 months	21	vision stabilized or improved in 87.5%, 25% showed 3 lines or greater improvement, when combined with PDT, improvement of 3 lines or greater reached 60%	Guyer et al 2003; Eyetech Study Group 2002
Phase III	0.3, 1.0, or 3.0 mg/eye	54 week	1186	efficacy demonstrated for all 3 doses without a dose-dependency relationship, 15%–24% improvement (depending on the evaluation) in number of patients that lost fewer than 15 letters of visual acuity, 2.2–9.7x greater risk of severe visual loss (≥30 letters), 10% improvement in patients that maintained or gained visual acuity, adverse effects accounting for severe loss of visual acuity in 0.1%	Gragoudas et al 2004; VISION Clinical Trial Group 2005

Abbreviations: PDT photodynamic therapy.